Quantumzyme Corp. (OTCQB: QTZM), a computational enzyme engineering company, announced its participation in the Catalysis and Chemical Engineering Conference (CCE-2026), scheduled for March 9–11, 2026, in Boston, MA. The company plans to showcase how its enzyme engineering platform is reshaping traditional chemical synthesis and enabling sustainable, cost-efficient pathways for pharmaceutical manufacturing, according to a press release.
Quantumzyme’s presence at CCE-2026 reflects its expanding role in advancing green chemistry solutions for the biomanufacturing sector, as global demand grows for low-waste, energy-efficient pharmaceutical production. The company will highlight its latest advancements in green ibuprofen synthesis, including the development of biocatalytic routes that reduce environmental impact and manufacturing costs. Additionally, Quantumzyme will present the ongoing expansion of its enzyme engineering platform to high-volume Active Pharmaceutical Ingredients (APIs), including new applications in chiral molecule synthesis supported by next-generation ketoreductase (KRED) enzymes, an area of growing significance for pharmaceutical and fine-chemical markets.
These developments demonstrate Quantumzyme’s continued progress in delivering practical, scalable solutions that support cleaner and more efficient pharmaceutical production. The company’s technology aligns with global sustainability and decarbonization goals, as well as U.S. initiatives to strengthen domestic API manufacturing capacity. Current API production often depends on legacy chemistries that generate significant waste and require high solvent usage. By enabling greener, more reliable, and locally scalable biocatalytic pathways, Quantumzyme’s platform aims to reduce waste and solvent consumption, lower carbon intensity in API production, improve process reliability and consistency, and support U.S. onshoring and supply-chain resilience for essential medicines.
Throughout CCE-2026, Quantumzyme plans to engage with researchers and academic collaborators, pharmaceutical manufacturers, process development and engineering teams, technology developers and innovation partners, and investors focused on green chemistry and biomanufacturing. These discussions are intended to explore partnerships that may accelerate the adoption of enzyme-based manufacturing approaches across high-volume API production.
“CCE-2026 provides an excellent platform to share our vision for sustainable chemical manufacturing,” said Naveen Kulkarni, Chief Executive Officer of Quantumzyme Corp. “We look forward to collaborating with global experts and demonstrating how our enzyme engineering technology may offer practical pathways toward cleaner and more efficient production.” Quantumzyme’s participation in CCE-2026 reflects its continued commitment to advancing next-generation biocatalysis and driving innovation across the pharmaceutical and specialty chemicals industries.
For more information, visit www.quantumzymecorp.com and the Company’s profile at www.otcmarkets.com/stock/QTZM.
